China · Delayed Price · Currency is CNY Kexing Biopharm Statistics
Total Valuation
Kexing Biopharm has a market cap or net worth of CNY 4.88 billion. The enterprise value is 5.73 billion.
| Market Cap | 4.88B |
| Enterprise Value | 5.73B |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jun 15, 2026 |
Share Statistics
Kexing Biopharm has 198.59 million shares outstanding. The number of shares has decreased by -0.39% in one year.
| Current Share Class | 198.59M |
| Shares Outstanding | 198.59M |
| Shares Change (YoY) | -0.39% |
| Shares Change (QoQ) | -2.33% |
| Owned by Insiders (%) | 51.51% |
| Owned by Institutions (%) | 12.04% |
| Float | 96.29M |
Valuation Ratios
The trailing PE ratio is 23.21 and the forward PE ratio is 39.66.
| PE Ratio | 23.21 |
| Forward PE | 39.66 |
| PS Ratio | 3.39 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 59.94 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 27.41 |
| EV / Sales | 3.98 |
| EV / EBITDA | 88.54 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.79.
| Current Ratio | 1.34 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 22.54 |
| Debt / FCF | -163.86 |
| Interest Coverage | -0.99 |
Financial Efficiency
Return on equity (ROE) is 11.71% and return on invested capital (ROIC) is -1.47%.
| Return on Equity (ROE) | 11.71% |
| Return on Assets (ROA) | -0.75% |
| Return on Invested Capital (ROIC) | -1.47% |
| Return on Capital Employed (ROCE) | -1.63% |
| Weighted Average Cost of Capital (WACC) | 5.46% |
| Revenue Per Employee | 1.30M |
| Profits Per Employee | 188,608 |
| Employee Count | 1,109 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 4.44 |
Taxes
In the past 12 months, Kexing Biopharm has paid 22.37 million in taxes.
| Income Tax | 22.37M |
| Effective Tax Rate | 9.79% |
Stock Price Statistics
The stock price has decreased by -39.34% in the last 52 weeks. The beta is 0.37, so Kexing Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -39.34% |
| 50-Day Moving Average | 20.30 |
| 200-Day Moving Average | 26.05 |
| Relative Strength Index (RSI) | 65.71 |
| Average Volume (20 Days) | 7,509,221 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kexing Biopharm had revenue of CNY 1.44 billion and earned 209.17 million in profits. Earnings per share was 1.06.
| Revenue | 1.44B |
| Gross Profit | 852.39M |
| Operating Income | -42.23M |
| Pretax Income | 228.63M |
| Net Income | 209.17M |
| EBITDA | 55.35M |
| EBIT | -42.23M |
| Earnings Per Share (EPS) | 1.06 |
Balance Sheet
The company has 609.87 million in cash and 1.46 billion in debt, with a net cash position of -849.34 million or -4.28 per share.
| Cash & Cash Equivalents | 609.87M |
| Total Debt | 1.46B |
| Net Cash | -849.34M |
| Net Cash Per Share | -4.28 |
| Equity (Book Value) | 1.84B |
| Book Value Per Share | 9.25 |
| Working Capital | 386.25M |
Cash Flow
In the last 12 months, operating cash flow was 81.48 million and capital expenditures -90.38 million, giving a free cash flow of -8.91 million.
| Operating Cash Flow | 81.48M |
| Capital Expenditures | -90.38M |
| Depreciation & Amortization | 97.57M |
| Net Borrowing | 69.73M |
| Free Cash Flow | -8.91M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 59.17%, with operating and profit margins of -2.93% and 14.52%.
| Gross Margin | 59.17% |
| Operating Margin | -2.93% |
| Pretax Margin | 15.87% |
| Profit Margin | 14.52% |
| EBITDA Margin | 3.84% |
| EBIT Margin | -2.93% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 1.02%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 1.02% |
| Dividend Growth (YoY) | 212.50% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 43.79% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.39% |
| Shareholder Yield | 1.41% |
| Earnings Yield | 4.28% |
| FCF Yield | -0.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kexing Biopharm has an Altman Z-Score of 2.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 3 |